Benchmark lowered the firm’s price target on HeartBeam (BEAT) to $5 from $8 and keeps a Speculative Buy rating on the shares after “a solid update” provided with Q1 results. However, while the recent $11.5M equity offering at 80c per share funds a runway at least through this year, the firm’s prior model had not assumed this level of dilution, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAT:
- HeartBeam Earnings Call: Funding Extends Runway, Trials Advance
- HeartBeam (NASDAQ: BEAT) Advances Commercial Launch, Reports First-Quarter 2026 Results
- HeartBeam reports Q1 EPS (12c) vs. (18c) last year
- HeartBeam (NASDAQ: BEAT) Launches Pilot Study for On-Demand 12-Lead ECG Patch in Coronary Artery Disease Patients
- HeartBeam initiates pilot study of first on-demand 12-lead ECG patch